Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Vienna Prograf and Endothelial Progenitor Cell Study
NCT00182559Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Apr 2004
- Primary completion
- May 2009
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in end stage renal disease (ESRD) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Change in endothelial progenitor cells at 24 months. Started Apr 2004; status: completed.
02
Drugs
tacrolimus
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT00182559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00182559.